MillerDHKhanOASheremataWA. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348: 15–23.
2.
KapposLRadueEWO’ConnorP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
3.
GorelikLLernerMBixlerS. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol2010; 68: 295–303.
4.
CarruthersRRotsteinDHealyB. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler2014;
5.
OlssonTAchironAAlfredssonL. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler2013; 19: 1533–1538.
6.
BogdanovicGPriftakisPHammarinAL. Detection of JC virus in cerebrospinal fluid (CSF) samples from patients with progressive multifocal leukoencephalopathy but not in CSF samples from patients with herpes simplex encephalitis, enteroviral meningitis, or multiple sclerosis. J Clin Microbiol1998; 36: 1137–1138.
7.
D’AgostinoRBJr.Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med1998; 17: 2265–2281.
